Inactive Instrument

Nutriband Inc Stock Other OTC

US67092M1099

Medical Equipment, Supplies & Distribution

Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

Market Cap	72.57M 65.76M 60.83M 54.88M 103M 6.84B 107M 731M 290M 3.66B 272M 267M 11.6B	P/E 2025	-8.39x	P/E 2026	-1.86x
Enterprise Value	68.24M 61.84M 57.2M 51.61M 97.25M 6.43B 101M 687M 272M 3.44B 256M 251M 10.91B	EV / Sales 2025	41.1x	EV / Sales 2026	26.5x
Free-Float	40.85%	Yield 2025 *	-	Yield 2026	-

08/10	Nutriband Files New Patent Application to Strengthen Intellectual Property Protection of Its Transdermal Abuse Deterrent Technology	CI
25/09	Nutriband Inc. Announces Appointment of Robert J. O'Neill to Advisory Board	CI
05/09	Nutriband Inc. Reports Earnings Results for the Second Quarter and Six Months Ended July 31, 2026	CI
12/06	Nutriband Inc. Reports Earnings Results for the First Quarter Ended April 30, 2026	CI
01/06	Nutriband Inc. announced that it has received $5 million in funding	CI
15/05	Active Intelligence and Nutriband Inc. Showcases Expanding Ai Wellness Product Portfolio and Announces New June Product Launches At Ecrm Conference	CI
30/04	Nutriband Inc. Reports Earnings Results for the Full Year Ended January 31, 2026	CI
19/03	Nutriband Ai Kinesiology Tapes Approves for Distribution and Sale in Costa Rica	CI
18/03	Nutriband Ai kinesiology tapes approved for distribution and sale in Costa Rica	RE
18/02	Nutriband Signs Exclusive Distribution Agreement with Innomedica for Aversa Fentanyl and All Sports Tape Products for Costa Rica	CI
17/02	Nutriband signs exclusive distribution agreement with Innomedica for Aversa fentanyl	RE
13/02	EarthVision Bio Solutions Inc. cancelled the acquisition of 90% stake in Pocono Pharmaceuticals, Inc. from Nutriband Inc..	CI
04/02	Nutriband Inc. Announces Election of New Directors	CI

13/10	Nutriband Inc. announces exercise of warrants at $6.43 for Gross Proceeds of $1,753,274	GL
08/10	Nutriband Files New Patent Application to Strengthen Intellectual Property Protection of Its Transdermal Abuse Deterrent Technology	GL
02/10	Nutriband Marks Five Years on Nasdaq – CEO Letter to Shareholders	GL
29/09	Nutriband CEO Gareth Sheridan Featured in New Nick Shirley Documentary Confronting America's Opioid Crisis	GL
25/09	Nutriband Appoints Decorated Navy SEAL and Veterans Health Advocate Robert J. O'Neill to Advisory Board	GL

Manager	Title	Age	Since
Gareth Sheridan CEO	Chief Executive Officer	35	01/01/2016
Serguei Melnik CEO	Chief Executive Officer	52	-
Gerald Goodman DFI	Director of Finance/CFO	77	02/09/2020

Director	Title	Age	Since
Serguei Melnik CHM	Chairman	52	21/01/2022
Stefan Mancas BRD	Director/Board Member	48	01/07/2018
Mark Hamilton BRD	Director/Board Member	38	01/07/2018

Nutriband Inc Stock Other OTC

Stocks

US67092M1099

Medical Equipment, Supplies & Distribution

Valuation: Nutriband Inc

Latest news: Nutriband Inc

Press Releases: Nutriband Inc

Managers and Directors: Nutriband Inc

Other Medical Equipment, Supplies & Distribution

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NUTRIBAND INC	-.--%	-.--%	-	-	72.57M
ABBOTT LABORATORIES	+1.18%	-4.47%	-15.76%	+15.48%	186B
MEDTRONIC PLC	+1.85%	-1.89%	+7.36%	+45.53%	124B
STRYKER CORPORATION	-0.88%	-7.59%	-15.71%	+13.16%	119B
ESSILORLUXOTTICA	+1.36%	-5.00%	-43.14%	+4.26%	91.43B
CENCORA, INC.	+2.96%	+5.70%	-1.21%	+81.72%	66.67B
BECTON, DICKINSON AND COMPANY	+1.08%	+2.10%	+13.49%	-7.08%	58.76B
IDEXX LABORATORIES, INC.	+0.89%	+5.00%	-1.31%	+64.26%	54.99B
HOYA CORPORATION	-0.68%	-0.62%	-2.41%	+56.27%	49.93B
MEDLINE INC.	-1.28%	-0.73%	-	-	35.13B
Average	+0.52%	-1.98%	-7.34%	+34.20%	87B
Weighted average by Cap.	+0.69%	-3.37%	-9.75%	+29.11%

	2025	2026
Net sales	2.14M 1.94M 1.79M 1.62M 3.05M 202M 3.16M 21.54M 8.54M 108M 8.03M 7.86M 342M	2.04M 1.85M 1.71M 1.54M 2.9M 192M 3M 20.51M 8.13M 103M 7.64M 7.48M 326M
Net income	-10.48M -9.5M -8.79M -7.93M -14.94M -988M -15.47M -106M -41.85M -528M -39.34M -38.5M -1.68B	-8.23M -7.46M -6.9M -6.22M -11.73M -776M -12.14M -82.86M -32.86M -415M -30.88M -30.23M -1.32B
Net Debt	-4.13M -3.74M -3.46M -3.12M -5.88M -389M -6.09M -41.54M -16.47M -208M -15.48M -15.15M -660M	-4.33M -3.92M -3.63M -3.27M -6.17M -408M -6.39M -43.59M -17.28M -218M -16.25M -15.9M -692M